Optinose $2.1M grant to deliver autism treatment from the nose to the brain

OptiNose's Norwegian affiliate has received a 12.3 million Norwegian krones ($2.1 million) award from the Research Council of Norway to fund its "nose-to-brain" research for the treatment of autism spectrum disorders. OptiNose's research is looking at the company's bi-directional dry powder delivery technology to deliver nasal oxytocin for the treatment of autism. This delivery system gets the drug deep into the nasal regions and into the brain via the olfactory nerve. OptiNose originated in Norway but moved its operations to the U.S. to improve its funding options. Press release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…